Boost Cancer Survival Rates and 62-Day Treatment Guarantee

Healthcare — Helps

moderate · moderate confidence

This policy targets several real weak spots in NHS cancer care — long waits, outdated equipment, too few nurses — and the evidence shows these genuinely harm patients. But the ambitions are very hard to deliver: the 62-day target hasn't been met since 2015, and fixing it requires workforce and capacity investment on an unprecedented scale.

The evidence

• The policy guarantees 100% of patients will start treatment within 62 days of urgent referral. — libdems.org.uk (manifesto) — “Introducing a guarantee that 100% of patients will be able to start treatment within 62 days from urgent referral”
• A new prostate cancer screening programme for higher-risk individuals is planned. — libdems.org.uk (manifesto) — “launching a new prostate cancer screening programme for those at higher risk”
• The 62-day treatment target has not been met in England since December 2015. — ons.gov.uk (government) — “This target has not been met in England since December 2015.”
• The share of patients waiting longer than 62 days has risen sharply, from 11% in 2012 to 33.4% in mid-2024. — ons.gov.uk (government) — “percentages of patients waiting longer than 62 days increase from 11.0% in Quarter 1 2012 to 33.4% in Quarter 2 2024 in England”
• The UK has fewer radiotherapy machines per capita than the European average. — radiotherapy.org.uk (media) — “The UK has 5.2 radiotherapy machines per million population, compared to a European average of 6-7.”
• UK cancer cure rates lag behind many European and North American countries partly because of under-resourcing of radiotherapy. — radiotherapy.org.uk (media) — “The UK's cancer cure rates lag behind many European and North American countries, partly due to under-resourcing of radiotherapy services.”
• One in four cancer patients diagnosed in the two years to September 2021 lacked specialist cancer nursing support. — theguardian.com (media) — “One in four patients diagnosed in the two years leading up to September 2021 (including 75,000 since the start of the pandemic) lacked specialist cancer nursing support.”
• Without workforce growth, the gap between cancer nurse capacity and patient need is projected to double to over 3,300 by 2030. — macmillan.org.uk (media) — “the gap between projected patient need and specialist cancer nurse capacity in England is expected to double to 3,371 by 2030”
• Prompt diagnosis and treatment are crucial for improving cancer survival, particularly at early stage. — news.cancerresearchuk.org (media) — “Prompt diagnosis and treatment are crucial for improving survival rates, especially for cancers diagnosed at an early stage.”
• Delays in starting radiotherapy worsen outcomes, with an average loss of tumour control probability of 1.6% per day of delay. — pmc.ncbi.nlm.nih.gov (government) — “an average calculated loss of tumor control probability of 1.6% per day of treatment prolongation.”
• Replacing and adding radiotherapy machines would lead to more patients receiving timely and effective treatment, which is critical for at least half of all cancer patients. — radiotherapy.org.uk (media) — “Replacing outdated equipment and increasing machine numbers would lead to more patients receiving timely and effective radiotherapy, which is a critical curative treatment for at least half of all cancer patients.”
• New machines often replace existing ones rather than expanding capacity, and funding for additional staff remains a gap. — pmc.ncbi.nlm.nih.gov (government) — “many new machines often replace existing ones rather than significantly expanding overall capacity, and there remains a lack of additional funding for crucial staff such as radiographers, physicists, and oncologists.”
• Achieving the 100% 62-day guarantee would require unprecedented investment in diagnostic capacity, workforce, and infrastructure. — nelcanceralliance.nhs.uk (media) — “achieving this would require unprecedented investment in diagnostic capacity, workforce, and infrastructure to manage the trebled number of urgent suspected cancer referrals seen over the last 14 years.”
• Treatment targets can create threshold effects where hospital behaviour changes to meet the metric rather than always prioritising clinical need. — pmc.ncbi.nlm.nih.gov (government) — “such targets can sometimes lead to "threshold effects," where hospital behavior is altered to meet the target, but not necessarily in a way that always prioritises clinical need most effectively.”
• Clinical trial approval times in the UK have already more than halved, falling from 91 to 41 days as of October 2025. — gov.uk (media) — “the average time to approve clinical trials in the UK has been more than halved, falling from 91 days to 41 days.”
• For treatments to reach patients, NICE and SMC approval is also required beyond MHRA, which the policy does not address. — targetovariancancer.org.uk (media) — “for treatments to reach patients, they also require approval from bodies like the National Institute for Health and Care Excellence (NICE) in England, Wales, and Northern Ireland, and the Scottish Medicines Consortium (S…”
• For every 1,000 men invited to prostate screening, up to two lives could be saved but up to 20 may be over-diagnosed and 12 may undergo unnecessary treatment. — lshtm.ac.uk (academic) — “for every 1,000 men invited to screening, up to two lives could be saved, but up to 20 men are likely to be over-diagnosed, and 12 of these may undergo unnecessary treatment over a 15-year follow-up period.”

Biggest unknown: Whether the workforce, diagnostic capacity, and funding required to meet a 100% 62-day guarantee can actually be delivered, given that even the existing 85% target has not been met in nearly a decade.

Our reading: The policy targets well-documented failures in NHS cancer care. The 62-day treatment standard has been unmet for nearly a decade and is worsening — a third of patients now wait too long. Delays demonstrably worsen survival. Radiotherapy capacity falls below European norms, and cancer nurse shortages are causing real harm, including cancelled treatment and patients ending up in A&E. The policy's stated commitments — upgrading machines, hiring nurses, speeding access to new treatments — directly address these bottlenecks, and the causal links between faster treatment and better survival are well-evidenced. However, the ambitions face serious delivery risks. A 100% 62-day guarantee is a step-change from the current 67%, and independent evidence says achieving it would require unprecedented investment in workforce and infrastructure that far exceeds what any equipment programme alone can provide. New machines frequently replace rather than add capacity, and staff shortages for radiographers, physicists, and oncologists remain unfunded by this policy. The MHRA trial approval improvement is already partly delivered, and NICE/SMC approval bottlenecks are untouched. The prostate screening element is the weakest component. The UK's own expert screening body advised against population-wide and at-risk-group screening in 2026, citing a poor harm-benefit ratio and overdiagnosis risks. If the policy's 'higher risk' programme contradicts this guidance, it could cause net harm rather than benefit in that strand. On balance, the suite of measures points to genuine improvement in cancer care access and outcomes if delivered — particularly on radiotherapy and nursing workforce — but the 100% 62-day guarantee is likely unachievable without far greater system-wide investment than stated, and the prostate screening element carries real clinical risk. A moderate improvement verdict is warranted, with low-to-moderate confidence on full delivery.